- Home
- » Tags
- » Cobimetinib
Top View
- Breast Cancer - Invasive Jane Doe 1/15/2020
- Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
- Table 1: Drug-Drug Interactions of Common Cardiac Drugs and Chemotherapeutic Agents*
- Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid- Derived Hematologic Malignancies
- What's New in Immunotherapy and Targeted Therapy?
- Treatment of Melanoma and Breast Cancer
- 3.-Igarashi-2017.JCB .Pdf
- NHS Borders NHS Borders Education Centre Planning & Performance Borders General Hospital Melrose Roxburghshire TD6 9BD 01896 825545 [email protected]
- Genomic Features of Exceptional Response in Vemurafenib
- A Phase Ib, Open Label, Dose-Escalation Study
- Results of Juvenile Animal Studies (JAS) and Impact on Anti-Cancer Medicine Development and Use in Children Project Report
- Venetoclax-Based Therapies for Acute Myeloid Leukemia T ∗ Veronica A
- A Monocentric Phase I Study of Vemurafenib Plus Cobimetinib Plus
- 5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAFV600 Mutation–
- Sorafenib Sensitizes Melanoma Cells to Vemurafenib Through Ferroptosis
- Roche to Share Important Oncology Data at European Cancer Congress
- (Cotellic) for Metastatic Melanoma
- The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- Public Assessment Report
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- A Novel Compound Which Sensitizes BRAF Wild-Type Melanoma Cells to Vemurafenib in a TRIM16-Dependent Manner
- Recently Approved Therapies and Drugs in Development
- Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis In
- Overview of Current Type I/II Kinase Inhibitors
- Mypathway Study: a Novel Precision Oncology Multiple Basket Trial
- Cobimetinib in Combination with Vemurafenib for Treating Unresectable Or Metastatic BRAF V600 Mutation-Positive Melanoma 1 Recommendations
- February 2021
- PERSONALIZED GENE PROFILE INDICATION: Lung Cancer
- Oncology Agents Policy #: Rx.01.67
- Oncology Therapy for the Generalist
- Annrheumdis-2019-216610.Full.Pdf
- Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- Cabozantinib and Cobimetinib to Be Featured in Fourteen Presentations at 2015 ASCO Annual Meeting
- Exelixis Announces Results from Cosmic-021 Trial of Cabozantinib in Combination with Atezolizumab in Multiple Advanced Solid Tumor Types
- Acute Myeloid Leukemia: Targets and Curability, So Close but a Journey So Far
- Therapeutic Resistance and Susceptibility Is Shaped by Cooperative Multi-Compartment Tumor Adaptation
- Resistance to Molecularly Targeted Therapies in Melanoma
- Cobimetinib + Vemurafenib in Patients with Colorectal Cancer with BRAF
- Cobimetinib (Cotellic®) Pronounced: “Koe-Bi-ME-Ti-Nib”
- BRAF-Mutant Cancers As a Paradigm Michelle L
- LOXO-101, a Selective TRKA/B/C Inhibitor, in Solid-Tumor Patients with NTRK Gene Fusions
- Quantification of Cobimetinib, Cabozantinib, Dabrafenib, Niraparib
- FOI 138 – 2122 Title: Incidence and Treatment of Melanoma and Renal Cell Carcinoma Date: June 2021 FOI Category: Pharmacy
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
- Policy Drug(S) Type of Change Brief Description of Policy Change
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- Roche to Present New Data from Its Broad Oncology Portfolio at The
- Phase II Study of Pazopanib in Combination with Paclitaxel in Patients with Metastatic Melanoma
- Full Prescribing Information for Serous Retinopathy and Retinal Vein Occlusion: Perform an COTELLIC
- Preclinical Evidence That Trametinib Enhances the Response to Anti-Angiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- Design and Implementation of an Intelligent Framework for Supporting Evidence-Based Treatment Recommendations in Precision Oncology
- Self Administered Oncology Agents Prior Authorization with Quantity
- Current Development Status of MEK Inhibitors
- Reference ID
- All ETCTN Trials
- Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
- NF1 Clinical Pipeline: Active Interventional Drug Therapies
- COTELLIC (Cobimetinib) Tablets, for Oral Use Serous Retinopathy and Retinal Vein Occlusion: Perform an Initial U.S
- In Combination with OPDIVO® (Nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
- Evaluation of Drug Therapy Costs for Patients with Breast Cancer, Melanoma and Renal Cell Carcinoma in Moscow in 2016-2017